Clinical trial
Phase III PEG-Intron in HIV-infected Patients (Study P00738)
NCT00035360 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00035360 |
|---|---|
| Title | Phase III PEG-Intron in HIV-infected Patients (Study P00738) |
| Official title | Phase 3 Study of PEG-Intron in Heavily Treatment-experienced, HIV-infected Patients |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, AIDS |
| Intervention type | Drug |
| Interventions | PEG-Intron |
| Enrollment | 49 |
| Start date | Mar 1, 2002 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | May 6, 2002 |
| Last update posted | Mar 10, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: